Physician profile
Benjamin C Long
NPI 1982102885
$8,837.73
in general payments reported to CMS, 2019-2025
58 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $1,327 · 2023: $1,526 · 2024: $2,320 · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,178 · Education: $171 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,177.70 |
| Education | $170.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $107.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,015.99 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Medtronic, INC. | $501.15 | 2021-2025 | Osteocool Rf Ablation System, Emprint |
| Novartis Pharmaceuticals Corporation | $487.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.05 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $369.01 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Gilead Sciences, INC. | $318.74 | 2022-2024 | Trodelvy |
| Genentech USA, INC. | $313.79 | 2022-2024 | Lunsumio, Polivy, Tecentriq |
| Abbvie INC. | $274.94 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $271.14 | 2021-2025 | Libtayo |
| Glaxosmithkline, LLC. | $265.84 | 2021-2025 | Ojjaara |
| Daiichi Sankyo INC. | $264.68 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $257.42 | 2022-2025 | |
| Eisai INC. | $248.19 | 2021-2025 | |
| Genentech, INC. | $214.69 | 2024-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Caris Mpi, INC. | $205.15 | 2025 | Mi Cancer Seek |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.02 | 2021-2025 | Verzenio |
| Galvanize Therapeutics, INC | $196.19 | 2025 | Aliya System |
| Beigene USA, INC. | $190.22 | 2021 | |
| Genzyme Corporation | $171.28 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $150.55 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $147.18 | 2022-2025 | Reblozyl |
| Stemline Therapeutics INC. | $146.04 | 2023-2024 | Orserdu |
| Tempus Ai, INC | $141.42 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $124.59 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $121.81 | 2023 | Fotivda |
| Incyte Corporation | $121.50 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Progenics Pharmaceuticals, INC. | $112.86 | 2023 | Pylarify |
| Takeda Pharmaceuticals U.S.A., INC. | $110.56 | 2024-2025 | Iclusig, Ninlaro |
| Foundation Medicine, INC. | $107.15 | 2023 | |
| Janssen Scientific Affairs, LLC | $106.93 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Karyopharm Therapeutics INC. | $104.91 | 2021-2025 | Xpovio |
| Genmab U.S., INC. | $104.45 | 2022-2025 | Tivdak |
| Amgen INC. | $104.25 | 2021-2024 | Prolia, Lumakras |
| Seagen INC. | $99.00 | 2022 | |
| Exelixis INC. | $67.70 | 2024-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $59.59 | 2022-2023 | |
| Springworks Therapeutics, INC. | $58.81 | 2024-2025 | Ogsiveo |
| Array Biopharma INC | $57.41 | 2024 | Braftovi, Mektovi, Tukysa |
| Jazz Pharmaceuticals INC. | $54.01 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $46.71 | 2024-2025 | Monoferric, Cosela |
| Ipsen Biopharmaceuticals, INC | $43.67 | 2021-2022 | |
| Kite Pharma, INC. | $43.38 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $41.29 | 2021 | |
| Taiho Oncology, INC. | $38.22 | 2021-2024 | |
| Blueprint Medicines Corporation | $37.13 | 2022-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.32 | 2024 | Gilotrif |
| Astellas Pharma US INC | $31.54 | 2025 | Vyloy |
| Sobi, INC | $29.08 | 2024 | |
| Myovant Sciences INC. | $21.97 | 2021 | |
| Sumitomo Pharma America, INC. | $21.75 | 2024 | Orgovyx |
| Pharmaessentia USA Corporation | $20.70 | 2025 | Besremi |
| Fresenius Kabi USA, LLC | $18.87 | 2024 | Stimufend |
| Kyowa Kirin, INC. | $18.25 | 2025 | |
| Novocure INC. | $17.74 | 2025 | Optune Lua (Novottf-200t) |
| Agios Pharmaceuticals, INC. | $16.06 | 2023 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $15.88 | 2022 | |
| Dova Pharmaceuticals | $12.99 | 2021 | |
| G1 Therapeutics, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.